TC Biopharm Signs LOI for CD-70 CAR-NK Technology Acquisition
Thursday, 4 April 2024, 13:18
TC Biopharm Shares Surge on Strategic Acquisition
TC Biopharm (TCBP) has secured a non-binding LOI to acquire the proprietary manufacturing process of two allogeneic CAR-NK therapeutics, highlighting the company's commitment to expanding its innovative therapeutic offerings. The focus on CD-70 CAR-NK technology underscores a strategic move towards enhancing TC Biopharm's position in the biopharmaceutical sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.